Site specific homogeneous with KSP inhibitors

US11806404B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Hans-Georg Lerchen · Leverkusen, DE
• Yolanda Cancho Grande · Leverkusen, DE
• Beatrix Stelte-Ludwig · Wülfrath, DE
• Anette SOMMER · Berlin, DE
• Christoph MAHLERT · Wuppertal, DE
• Anne-Sophie REBSTOCK · Écully, FR
• Simone Greven · Dormagen, DE
• Nils Griebenow · Milford, US
• Jan Tebbe · Cologne, DE
• Oliver Kensch · Pulheim, DE

Key dates

• Filing date: Feb 3, 2021
• Grant date: Nov 7, 2023
• Expiry date: Jan 22, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K16/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to site specific homogeneous binder drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes for preparing these conjugates, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.